CAJ | 학술논문

目的：探讨紫杉醇联合顺铂治疗晚期老年卵巢癌的临床疗效。方法选取2011年6月至2014年1月在我院治疗的晚期老年卵巢癌患者102例作为研究对象，按照治疗方法的不同分为联合组和对照组，联合组51例，给予紫杉醇联合顺铂治疗，对照组51例，单用紫杉醇治疗。观察并比较两组的治疗效果和不良反应。结果联合组和对照组的治疗总有效率分别为86.27％、66.67％，联合组显著高于对照组，差异具有统计学意义（P<0.05）。联合组患者术后1年和2年生存率分别为78.43％（40/51）、64.70％（33/51），显著高于对照组（50.98％、41.18％），差异均有统计学意义（P<0.05）。两组患者均出现不同程度的恶心、呕吐、腹泻，联合组和对照组不良反应的发生率分别为29.41％、25.49％，差异无统计学意义（P>0.05）。结论紫杉醇联合顺铂治疗晚期老年卵巢癌患者，能够有效提高治疗效果，且安全性高，值得临床推广应用。
목적：탐토자삼순연합순박치료만기노년란소암적림상료효。방법선취2011년6월지2014년1월재아원치료적만기노년란소암환자102례작위연구대상，안조치료방법적불동분위연합조화대조조，연합조51례，급여자삼순연합순박치료，대조조51례，단용자삼순치료。관찰병비교량조적치료효과화불량반응。결과연합조화대조조적치료총유효솔분별위86.27％、66.67％，연합조현저고우대조조，차이구유통계학의의（P<0.05）。연합조환자술후1년화2년생존솔분별위78.43％（40/51）、64.70％（33/51），현저고우대조조（50.98％、41.18％），차이균유통계학의의（P<0.05）。량조환자균출현불동정도적악심、구토、복사，연합조화대조조불량반응적발생솔분별위29.41％、25.49％，차이무통계학의의（P>0.05）。결론자삼순연합순박치료만기노년란소암환자，능구유효제고치료효과，차안전성고，치득림상추엄응용。
Objective To investigate the clinical efficacy of paclitaxel and cisplatin in the treatment of elderly patients with advanced ovarian cancer. Methods A total of 102 elderly patients with ovarian cancer admitted in our hospital between June 2011 and January 2014 were enrolled in this study. They were divided into combined group and control group accord-ing to the treatment methods. 51 patients in the combined group were given paclitaxel combined with cisplatin treatment, and other 51 cases in the control group were given paclitaxel alone. The clinical efficacy, 1-and 2-year survival after treatment and incidences of adverse reactions were observed and compared between the two groups. Results The total efficiency of com-bined group was 86.27%, significantly higher than that of the control group (66.67%, P<0.05). The 1-and 2-year survival rates after treatment of combined group were respectively 78.43%, 64.70%, which were both obviously higher than those of the control group (50.98%, 41.18%, P<0.05). Nausea, vomiting and diarrhea were observed in both groups, but no statistical dif-ferences were observed in the incidence rates of these adverse reactions between the two groups (29.41%vs 25.49%, P>0.05). Conclusion Paclitaxel combined cisplatin could effectively enhance the clinical efficacy of elderly patients with advanced ovarian cancer. The combination of two also had good safety and thus was worth of being generalized in clinic.